Aptamer News and Research

RSS

Licensing agreed for Optimer as novel vaccine adjuvant

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has entered into a global licensing agreement with the University of Glasgow for the commercial use of a developed panel of Optimer binders as vaccine adjuvants in the swine health sector.

30 Apr 2025

New biosensor offers fast detection of H5N1 in farm air

As highly pathogenic H5N1 avian influenza continues to spread in the U.S., posing serious threats to dairy and poultry farms, both farmers and public health experts need better ways to monitor for infections, in real time, to mitigate and respond to outbreaks.

24 Apr 2025

Drug-carrying DNA aptamers offer dual action against leukemia stem cells

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois Urbana-Champaign report.

3 Apr 2025

New method uses DNA sequencing for precise metabolite measurement

Researchers at the University of Toronto have invented a new method that uses DNA sequencing to measure metabolites. This enables rapid and precise analysis of biological compounds, such as sugars, vitamins, hormones and the hundreds of other metabolites that are critical for health.

4 Feb 2025

New Optimer contract to develop bioanalytical tools for RNA therapy

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the signing of a new development contract with a rare disease biopharmaceutical company.

From Aptamer Group 23 Dec 2024

DNA-based nanorobotic hand could block viruses and enable rapid diagnostics

A tiny, four-fingered "hand" folded from a single piece of DNA can pick up the virus that causes COVID-19 for highly sensitive rapid detection and can even block viral particles from entering cells to infect them, University of Illinois Urbana-Champaign researchers report.

27 Nov 2024

Aptamer extends agreement with genetic medicines customer

Aptamer's Optimer technology achieves key milestones in genetic medicine delivery, enhancing targeting specificity and advancing towards preclinical studies.

From Aptamer Group 7 Nov 2024

Study uncovers biological drivers of plasma proteins, offering new insights for disease biomarkers and drug discovery

Researchers mapped the biological influences on 4,775 plasma proteins, revealing the interplay of modifiable and non-modifiable factors, with key implications for disease biomarkers and drug targets.

30 Sep 2024

NIAID awards grants for 10 projects to improve diagnostic tools for syphilis

The National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) has awarded grants for 10 projects to improve diagnostic tools for congenital and adult syphilis - conditions currently diagnosed with a sequence of tests, each with limited precision.

3 Sep 2024

Aptamer extends contract with Unilever to progress Optimer for deodorant development

Lab-test results of Optimer indicate good applicability in deodorant products.

From Aptamer Group 3 Sep 2024

Exosome-encapsulated fluorescent sensors enable advanced brain imaging in Alzheimer's research

Neurotransmitter levels in the brain can indicate brain health and neurodegenerative diseases like Alzheimer's.

31 Jul 2024

Novel DNA aptamers of melanopsin developed to regulate circadian rhythm

DNA aptamers of melanopsin that regulate the clock hands of biological rhythms were developed by the Toyohashi University of Technology and the National Institute of Advanced Industrial Science and Technology (AIST) group.

12 Jul 2024

Update on progress in Unilever partnership

Aptamer Group, the developer of novel Optimer® binders to enable innovation in the life sciences industry, is providing an update on the partnership with Unilever to deliver Optimer binders for cosmetic applications.

From Aptamer Group 9 Jul 2024

Agreement to explore Optimer vehicles for targeted delivery of siRNA

New collaboration will evaluate Aptamer’s fibrotic liver delivery vehicles with siRNA.

From Aptamer Group 9 Jul 2024

Innovative aptamer cream shows promise in treating allergic contact dermatitis in mice

Researchers at the University of Bonn have isolated a DNA molecule that is suitable for combating allergic contact dermatitis in mice.

4 Jul 2024

Partnership with Microsaic Systems for Optimer-enabled water monitoring

New binders will be developed to multiple waterborne pathogens. Optimer will support continuous water monitoring for rapid detection.

From Aptamer Group 14 Jun 2024

Aptamer and Timser partner to deliver world’s first blood test for cervical cancer

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has signed an agreement with Timser Group, a pharmaceutical company focused on women’s health, with a deal value of up to £465,000.

From Aptamer Group 22 May 2024

Top pharmaceutical company evaluates Optimer for precision liver medicine

Optimer delivery vehicle has been shipped to a pharma partner for external evaluation.

From Aptamer Group 22 Apr 2024

Patent submission for Optimer® binders in cosmetic products

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that it has filed a patent application to protect the recently developed Optimer binder sequences for novel applications in fast moving consumer goods generated as part of its partnership with Unilever.

From Aptamer Group 10 Apr 2024

DNA aptamer-based sensors can accurately detect trace amounts of fentanyl, heroin, and cocaine

Researchers from North Carolina State University have developed a new generation of high-performance DNA aptamers and highly accurate drug sensors for cocaine and other opioids.

5 Mar 2024